Potent, highly selective, and non-thiol inhibitors of protein geranylgeranyltransferase-I

Journal of Medicinal Chemistry

Volumn 42, Issue 8, 1999, Pages 1333-1340

  Vasudevan, Anil ^c   Qian, Yimin ^c   Vogt, Andreas ^c   Blaskovich, Michelle A ^b   Ohkanda, Junko ^a   Sebti, Said M ^b   Hamilton, Andrew D ^a  

^a YALE UNIVERSITY   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[N (1H IMIDAZOL 2 YL)METHYLENEAMINO] 2 (1 NAPHTHYL)BENZOYL]LEUCINE METHYL ESTER; 4 NITRO 2 (1 NAPHTHYL)BENZOIC ACID METHYL ESTER; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; GERANYLTRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG POTENCY; DRUG SPECIFICITY; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SPECIFICITY; STRUCTURE ACTIVITY RELATION;

3T3 CELLS; ALKYL AND ARYL TRANSFERASES; ANIMALS; DRUG DESIGN; ENZYME INHIBITORS; GTP-BINDING PROTEINS; IMIDAZOLES; LEUCINE; MICE; MOLECULAR MIMICRY; PROTEIN ISOPRENYLATION; RAP GTP-BINDING PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033594336     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9900873     Document Type: Article

References (26)

1. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: steady-state kinetics and substrate binding. Biochemistry 1997, 36, 4552-4557. Yokoyama, K.; McGeady, P.; Gelb, M. H. Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. Biochemistry 1995, 34, 1344-1354. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: overproduction, purification, and characterization. Arch. Biochem. Biophys. 1995, 321, 182-190. Zhang, F. L.; Moomaw, J. F.; Casey, P. J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type-I. J. Biol. Chem. 1994, 269, 23465-23470.
2. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: steady-state kinetics and substrate binding. Biochemistry 1997, 36, 4552-4557. Yokoyama, K.; McGeady, P.; Gelb, M. H. Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. Biochemistry 1995, 34, 1344-1354. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: overproduction, purification, and characterization. Arch. Biochem. Biophys. 1995, 321, 182-190. Zhang, F. L.; Moomaw, J. F.; Casey, P. J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type-I. J. Biol. Chem. 1994, 269, 23465-23470.
3. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: steady-state kinetics and substrate binding. Biochemistry 1997, 36, 4552-4557. Yokoyama, K.; McGeady, P.; Gelb, M. H. Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. Biochemistry 1995, 34, 1344-1354. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: overproduction, purification, and characterization. Arch. Biochem. Biophys. 1995, 321, 182-190. Zhang, F. L.; Moomaw, J. F.; Casey, P. J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type-I. J. Biol. Chem. 1994, 269, 23465-23470.
4. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: steady-state kinetics and substrate binding. Biochemistry 1997, 36, 4552-4557. Yokoyama, K.; McGeady, P.; Gelb, M. H. Mammalian protein geranylgeranyltransferase-I: substrate specificity, kinetic mechanism, metal requirements, and affinity labeling. Biochemistry 1995, 34, 1344-1354. Sirtan, W. G.; Poulter, C. D. Yeast protein geranylgeranyltransferase type-I: overproduction, purification, and characterization. Arch. Biochem. Biophys. 1995, 321, 182-190. Zhang, F. L.; Moomaw, J. F.; Casey, P. J. Properties and kinetic mechanism of recombinant mammalian protein geranylgeranyltransferase type-I. J. Biol. Chem. 1994, 269, 23465-23470.
5. Casey, P. J. Biochemistry of protein prenylation. J. Lipid Res. 1992, 33, 1731-1740.
6. Witter, D. J.; Poulter, C. D. Yeast geranylgeranyltransferase type-II: steady state kinetic studies of the recombinant enzyme. Biochemistry 1996, 35, 925-932.
7. Gibbs, J, B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77, 175-178. Buss, J. E.; Marsters, J. C. Farnesyltransferase inhibitors: the successes and suprises of a new class of potential cancer chemotherapeutics. Chem. Biol. 1995, 2, 787-791. Sebti, S. M.; Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 1997, 71, 1-12.
8. Gibbs, J, B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77, 175-178. Buss, J. E.; Marsters, J. C. Farnesyltransferase inhibitors: the successes and suprises of a new class of potential cancer chemotherapeutics. Chem. Biol. 1995, 2, 787-791. Sebti, S. M.; Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 1997, 71, 1-12.
9. Gibbs, J, B.; Oliff, A.; Kohl, N. E. Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic. Cell 1994, 77, 175-178. Buss, J. E.; Marsters, J. C. Farnesyltransferase inhibitors: the successes and suprises of a new class of potential cancer chemotherapeutics. Chem. Biol. 1995, 2, 787-791. Sebti, S. M.; Hamilton, A. D. Inhibition of Ras prenylation: a novel approach to cancer chemotherapy. Pharmacol. Ther. 1997, 71, 1-12.
10. Olson, M. F.; Ashworth, A.; Hall, A. An essential role for Rho, Rac and Cdc42 GTPases in cell cycle progression through G1. Science 1995, 269, 1270-1272.
11. Vogt, A.; Qian, Y.; McGuire, T. F.; Blaskovich, M. A.; Hamilton, A. D.; Sebti, S. M. Protein geranylgeranylation, not farnesylation, is required for G1 to S phase transition in mouse fibroblasts. Oncogene 1996, 13, 1991-1999.
12. Sun, J.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Both farnesyltransferase and geranylgeranyltransferase are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to supress human tumor growth in nude mouse xenografts. Oncogene 1998, 16, 1467-1473.
13. Stark, W. W.; Blaskovich, M. A.; Johnson, B. A.; Vasudevan, A.; Hamilton, A. D.; Sebti, S. M.; Davies, P. Inhibition of geranylgeranylation, but not farnesylation, promotes apoptosis in vascular smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 1998, 275, L55-L63.
14. Finder, J. D.; Litz, J. L.; Blaskovich, M. A.; McGuire, T. F.; Qian, Y.; Hamilton, A. D.; Davies, P.; Sebti, S. M. Inhibition of protein geranylgeranylation causes a superinduction of nitric oxide synthase by IL-1β in artery smooth muscle cells. J. Biol. Chem. 1997, 272, 13484-13488.
15. Qian, Y.; Sebti, S. M.; Hamilton, A. D. Peptidomimetic inhibitors of farnesyltransferase: An approach to new antitumor agents. In Advances in Peptidomimetic Chemistry; Abell, A., Ed.; Jai Press: Greenwich, CT, 1997; Vol. 1, pp 165-192.
16. Lerner, E. C.; Zhang, T. T.; Knowles, D.; Qian, Y.; Hamilton, A. D.; Sebti, S. M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resisitant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltranferase I inhibitor in human cell lines. Oncogene 1997, 15, 1283-1288.
17. Ratemi, E. S.; Dolence, J. M.; Poulter, C. D.; Veders, J. C. Synthesis of protein farnesyltransferase and protein geranylgeranyltransferase inhibitors: rapid access to chaetomellic acid A and its analogues. J. Org. Chem. 1996, 61, 6296-6301. Macchia, M.; Jannitti, N.; Gervasi, G.; Danesi, R. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. J. Med. Chem. 1996, 39, 1352-1356.
18. Ratemi, E. S.; Dolence, J. M.; Poulter, C. D.; Veders, J. C. Synthesis of protein farnesyltransferase and protein geranylgeranyltransferase inhibitors: rapid access to chaetomellic acid A and its analogues. J. Org. Chem. 1996, 61, 6296-6301. Macchia, M.; Jannitti, N.; Gervasi, G.; Danesi, R. Geranylgeranyl diphosphate-based inhibitors of post-translational geranylgeranylation of cellular proteins. J. Med. Chem. 1996, 39, 1352-1356.
19. Lerner, E. C.; Qian, Y.; Blaskovitch, M.; Fossum, R.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/ Raf complexes. J. Biol. Chem. 1995, 270, 26802-26806. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferases inhibitors. J. Med. Chem. 1996, 39, 217-223.
20. Lerner, E. C.; Qian, Y.; Blaskovitch, M.; Fossum, R.; Vogt, A.; Sun, J.; Cox, A. D.; Der, C. J.; Hamilton, A. D.; Sebti, S. M. Ras CAAX peptidomimetic FTI277 selectively blocks oncogenic Ras signaling by inducing cytoplasmic accumulation of inactive Ras/ Raf complexes. J. Biol. Chem. 1995, 270, 26802-26806. Qian, Y.; Vogt, A.; Sebti, S. M.; Hamilton, A. D. Design and synthesis of non-peptide Ras CAAX mimetics as potent farnesyltransferases inhibitors. J. Med. Chem. 1996, 39, 217-223.
21. (a) Lerner, E. C.; Qian, Y.; McGuire, T. F.; Hamilton, A. D.; Sebti, S. M. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase inhibitor. J. Biol. Chem. 1995, 270, 26770-26773.
22. (b) Qian, Y.; Vogt, A.; Vasudevan, A.; Sebti, S.; Hamilton, A. D. Selective inhibition of type-I geranylgeranyltransferase in vitro and in whole cells by CAAL peptidomimetics. Bioorg. Med. Chem. 1998, 6, 293-299.
23. Zhang, F. L.; Casey, P. J. Influence of metal ions on substrate binding and catalytic activity of mammalian protein geranylgeranyltransferase type-I. Biochem. J. 1996, 320, 925-932.
24. Cecchi, R.; Ciabatti, R.; Favara, D.; Barone, D.; Baldoli, E. Imidazolyl derivatives of enalapril as potential angiotensin converting enzyme inhibitors. Farmaco Ed. Sci. 1985, 40, 541-554.
25. Hunt, J. T.; Lee, V. G.; Leftheris, K.; Seizinger, B.; Carboni, J.; Mabus, J.; Ricca, C.; Yan, N.; Manne, V. Potent, cell-active, non-thiol tetrapeptide inhibitors of farnesyltransferase. J. Med. Chem. 1996, 39, 353-358.
26. The exceptions were ethers 13 and 14 and aminomethylenes 11 and 12 which were prepared from the corresponding 4-hydroxy-and 4-cyanobenzoic acid derivatives, respectively.